Haystack Oncology and Alliance Foundation Trials collaborate to use Haystack MRD™ technology in phase II clinical trial for unresectable stage III NSCLC

BALTIMORE, Jan. 8, 2024 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics company, has entered into a collaboration with Alliance Foundation Trials, LLC for research use of Haystack...

Related Keywords

United States ,Baltimore ,Maryland ,Hamburg ,Germany ,Helsinki ,Eteläuomen Läi ,Finland ,Americans ,Dan Edelstein ,David Kozono ,Genentech ,Alliance Foundation Trials ,Quest Diagnostics ,Johns Hopkins School Of Medicine ,Oncology Committee Co ,Alliance Immuno ,Roche Group ,Alliance For Clinical Trials In Oncology ,Haystack Oncology ,Vice President ,General Manager ,Alliance Immuno Oncology Committee ,Johns Hopkins School ,Foundation Trials ,Clinical Trials ,Markets ,